192 related articles for article (PubMed ID: 19265199)
1. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.
Sun J; Pedersen M; Rönnstrand L
J Biol Chem; 2009 Apr; 284(17):11039-47. PubMed ID: 19265199
[TBL] [Abstract][Full Text] [Related]
2. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
Lindblad O; Kazi JU; Rönnstrand L; Sun J
Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
[TBL] [Abstract][Full Text] [Related]
3. KIT
Phung B; Kazi JU; Lundby A; Bergsteinsdottir K; Sun J; Goding CR; Jönsson G; Olsen JV; Steingrímsson E; Rönnstrand L
Mol Cancer Res; 2017 Sep; 15(9):1265-1274. PubMed ID: 28584020
[TBL] [Abstract][Full Text] [Related]
4. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
5. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
[TBL] [Abstract][Full Text] [Related]
6. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
9. SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation.
Rupar K; Moharram SA; Kazi JU; Rönnstrand L
Sci Rep; 2018 Apr; 8(1):6405. PubMed ID: 29686302
[TBL] [Abstract][Full Text] [Related]
10. Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling.
Kazi JU; Agarwal S; Sun J; Bracco E; Rönnstrand L
J Cell Sci; 2014 Feb; 127(Pt 3):653-62. PubMed ID: 24284075
[TBL] [Abstract][Full Text] [Related]
11. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
13. KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.
Rajan V; Prykhozhij SV; Pandey A; Cohen AM; Rainey JK; Berman JN
Br J Haematol; 2023 Sep; 202(5):960-970. PubMed ID: 35245395
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation.
Agarwal S; Kazi JU; Rönnstrand L
J Biol Chem; 2013 Aug; 288(31):22460-8. PubMed ID: 23803604
[TBL] [Abstract][Full Text] [Related]
15. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
16. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.
Piao X; Paulson R; van der Geer P; Pawson T; Bernstein A
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14665-9. PubMed ID: 8962111
[TBL] [Abstract][Full Text] [Related]
18. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation.
Timokhina I; Kissel H; Stella G; Besmer P
EMBO J; 1998 Nov; 17(21):6250-62. PubMed ID: 9799234
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase and Src family kinases are required for phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling.
Liang X; Wisniewski D; Strife A; Shivakrupa ; Clarkson B; Resh MD
J Biol Chem; 2002 Apr; 277(16):13732-8. PubMed ID: 11825908
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling.
Kazi JU; Vaapil M; Agarwal S; Bracco E; Påhlman S; Rönnstrand L
Cell Signal; 2013 Sep; 25(9):1852-60. PubMed ID: 23707526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
